Lipidfiltration - Safe and effective methodology to perform lipid-apheresis

Transfusion and Apheresis Science

Volumn 30, Issue 3, 2004, Pages 245-254

  Klingel, Reinhard ^a   Mausfeld, Patrick ^a   Fassbender, Cordula ^a   Goehlen, Britta ^a  

^a Apheresis Research Institute   (Germany)

Author keywords

Coronary artery disease; Double filtration plasmapheresis; Fibrinogen; Hemorheology; Hypercholesterolemia; LDL apheresis; Lipid apheresis; Lipidfiltration; Low density lipoprotein cholesterol; Membrane differential filtration

Indexed keywords

FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMA PROTEIN; TRIACYLGLYCEROL;

ALLERGIC REACTION; APHERESIS; BLEEDING; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EDEMA; FAMILIAL HYPERCHOLESTEROLEMIA; GERMANY; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; LIPID FILTRATION; NAUSEA AND VOMITING; PLASMAPHERESIS; REIMBURSEMENT;

BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; PLASMAPHERESIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 2542631151     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2004.01.008     Document Type: Conference Paper

References (49)

1. Thompson G.R., Maher V.M.G., Matthews S., Kitano Y., Neuwirth C., Shortt M.B., et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 345:1995;811-816
2. Hoffmann U., Derfler K., Haas M., Stadler A., Brady T.J., Kostner K. Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography. Am J. Cardiol. 91:2003;461-464
3. Kroon A.A., Aengevaeren W.R., van der Werf T., Uijen G.J., Reiber J.H., Bruschke A.V., et al. LDL apheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93:1996;1826-1835
4. Mabuchi H., Koizumi J., Shimizu M., et al. Long-term Efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 82:1998;1489-1495
5. Matsuzaki M., Hiramori K., Imaizumi T., Kitabatake A., Hishida H., Nomura M., et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia. The low-density lipoprotein-apheresis coronary morphology and reserve trial (LACMART). J. Am. Coll. Cardiol. 40:2002;220-227
6. Schuff-Werner P., Gohlke H., Bartmann U., Baggio G., Corti M.C., Dinsenbacher A. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentration and the course of coronary heart disease. Eur. J. Clin. Invest. 24:1994;724-732
7. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
8. Schettler V, Wieland E, Armstrong VW, Kleinoeder T, Grunewald RW, Müller GA, and the Participants of the Göttingen Consensus Conferences: Bosch T, Creutzfeld C, Hilgers R, Julius U, Kassner U, Keller C, Klingel R, Köster W, Messner H, Otto C, Ramlow W, Richter WO, Ritter MM, Schäfer P, Schuff-Werner P, Seidel D, Stegmayr B, Thiery J, Vogt B, von der Heyde F. First steps toward the establishment of a german low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management. Ther Apher 2002;6:381-3
9. Bosch T., Schmidt B., Kleophas W., Otto V., Samtleben W. LDL hemoperfusion - a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Artif. Organs. 21:1997;1060-1065
10. Godehardt E, Messner H, Wallstab UH. Extracorporeal LDL cholesterol elimination by membrane differential filtration. A retrospective analysis of 1702 treatments. In: Gotto AM Jr, Mancini M, Richter WO, Schwandt P, editors. Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease, 4th International Symposium, Munich 1992. Karger: Basel; 1993. p. 208-12
11. Jansen M., Banyai S., Schmaldienst S., et al. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL apheresis system for the treatment of familial hypercholesterolemia. Wien. Klin. Wochenschr. 112/2:2000;61-69
12. Julius U., Metzler W., Pietzsch J., Faßbender T., Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: Lipidfiltration and HELP. Int. J. Artif. Organs. 25:2002;1180-1188
13. Kobayashi A., Nakatani M., Furuyoshi S., Tani N. In vitro evaluation of dextran sulfate cellulose beads for whole blood infusion low-density lipoprotein-hemoperfusion. Ther. Apher. 6:2002;365-371
14. Schmaldienst S., Banyai S., Stulnig T.M., et al. Prospective randomised cross-over comparison of three LDL apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis. 151:2000;493-499
15. Agishi T., Kaneko J., Hasuo Y., Hayasaka Y., Sanaka T., Ota K., et al. Double filtration plasmapheresis with no or minimal amount of blood derivative for substitution. Sieberth H.G. Plasma exchange, plasmapheresis, plasmaseparation. 1980;53-57 Schattauer Verlag, Stuttgart
16. Nosé Y, Malchesky PS, Asanuma Y, Zawicki I. Plasma filtration detoxification on hepatic patients: its optimal operating conditions. In: Gurland HJ, Heinze V, Lee HA, editors. Therapeutic plasma exchange, vol. 4. Springer-Verlag, Basel; 1981. p. 125-35
17. Matsuda Y., Malchesky P.S., Nose Y. Low-density lipoprotein removal methods by membranes and future perspectives. Artif. Organs. 20:1996;346-355
18. Matsuda Y., Sueoka A., Nose Y. An effective LDL removal filter for the treatment of hyperlipidemia. Artif. Organs. 19:1995;129-134
19. Donner MG, Richter O, Schwandt P. Plasma lipoproteins under LDL apheresis by cascade filtration. In: 66th Congress of the European Atherosclerosis Society, Atherosclerosis; 1996. p. 209
20. Suzuki M., Yamane S., Matsugane T., Nobuto T., Azuma N., et al. Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients. Artif. Organs. 20:1996;296-302
21. Baeyer H von, Schartl M, Schwerdtfeger R, Bimmermann A, Milenz W. Results of long-term treatment of severe familial hypercholesrolemia with differential filtration LDL apheresis. In: Gotto AM, Mancini M, Richter WO, Schwandt P, editors. Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease 4. 4th International Symposium, Munich, 1992; Karger: Basel; 1993 p. 208-12
22. Franceschini G., Busnach G., Vaccarino V., Calabresi L., Gianfranceschi G., Sirtori C.R. Apheretic treatment of severe familial hypercholesterolemia: comparison of dextran sulfate cellulose and double membrane filtration methods for low density lipoprotein removal. Atherosclerosis. 73:1988;197-202
23. Geiss H.C., Parhofer K.G., Donner M.G., Schwandt P. Low density lipoprotein apheresis by membrane differential filtration (cascade filtration). Ther. Apher. 3:1999;199-202
24. Parhofer K.G., Geiss H.C., Schwandt P. Efficacy of different low-density lipoprotein apheresis methods. Ther. Apher. 4:2000;382-385
25. Jaeger B.R. Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostatsis. Ther. Apher. 5:2001;207-211
26. Jaeger B.R., Goehring P., Schirmer J., Uhrig S., Lohse P., Kreuzer E., et al. Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: a different pathophysiological approach. Ther. Apher. 5:2001;252-259
27. Krebs A., Zellner D., Braun N., et al. Multicentre comparison of 5 methods for long-term lipid apheresis between years 1986 to 2001 in 20 patients. Kidney Blood Press. Res. 24:2001;313-314
28. Yamane S., Matsugane T., Motohashi K., et al. Double Filtration Plasmapheresis maintains normal adhesion molecule levels. Ther. Apher. 2:1998;224-227
29. Poredos P., Zizek B. Plasma viscosity increase with progression of peripheral arterial atherosclerotic disease. Angiology. 47:1996;253-259
30. Otto C., Ritter M.M., Richter W.O., Minkenberg R., Schwandt P. Hemorheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks. Metabolism. 50:2001;166-170
31. Koenig W., Ernst E. The possible role of hemorheology in atherogenesis. Atherosclerosis. 94:1992;93-107
32. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL-apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation. 95:1997;76-82
33. Messner H, Godehardt E, Köbberling J, Hein D. Membrane differential filtration in extracorporeal LDL-cholesterol elimination. In: Gotto AM, Mancini M, Richter WO, Schwandt P, editors. Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease 4. Proceedings of the 4th International Symposium, Munich, 1992; Karger: Basel; 1993. p. 204-7
34. Schamberger B.M., Geiss H.C., Ritter M.M., Schwandt P., Parhofer K.G. Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. J. Lipid Res. 41:2000;727-733
35. Donner M.G., Parhofer K.G., Richter W.O., Schwandt P. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis. Metabolism. 48:1999;881-886
36. Lepage S., Nigon F., Bonnefont-Rousselot D., et al. Oxidizability of atherogenic low-density lipoprotein subspecies in severe familial hypercholesterolemia: impact of long-term low-density lipoprotein apheresis. J. Cardiovasc. Pharmacol. Ther. 5:2000;87-103
37. Goldman L., Gordon D.J., Rifkind B.M., Hulley S.B., Detsky A.S., Goodman D.S., et al. Cost and health implications of cholesterol lowering. Circulation. 85:1992;1960-1968
38. Gotto AM, Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the interdisciplinary council on reducing the risk for coronary heart disease. Ninth council meeting. Circulation 1999;99:E1-7
39. Richter W.O., Donner M.G., Höfling B., Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism. 74:1998;863-868
40. Banyai S., Streicher J., Strobl W., Gabriel H., Gottsauner-Wolf M., Rohac M., et al. Therapeutic efficiency of lipoprotein (a) reduction by low-density lipoprotein immunoapheresis. Metabolism. 47:1998;1058-1064
41. Straube R., Gäckler D., Thiele A., Muselmann L., Kingreen H., Klingel R. Membrane differential filtrationj is safe and effective for the long-term treatment of Refsum syndrome an update of treatment modalities and pathophysiological cognition. Transf. Apher. Sci. 29:2003;85-91
42. Gutsche H.U., Siegmund J.B., Hoppmann I. Lipapheresis, an immunoglobulin sparing treatment for Refsum's disease. Acta Neurol. Scand. 94:1996;190-193
43. Klingel R., Göhlen B., Schwarting A., Himmelsbach F., Straube R. Differential indication of lipoprotein apheresis during pregnancy. Ther. Apher. Dial. 7:2003;359-364
44. Hummelsheim T, Borberg H, Brunner R, Oette K: Acute changes of haemorheological parameters by LDL apheresis: specific immunoadsorption versus cascade filtration. Infusionsther Transfusionsmed 22:1995;42-44. In: Gotto AM, Mancini M, Richter WO, Schwandt P, editors. Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease 4. Proceedings of the 4th International Symposium Munich, 1992. Karger: Basel; 1993 p. 194-203; 204-7
45. Eisenhauer T., Armstrong V.W., Wieland H., Fuchs C., Nebendahl K., Scheler F. Selective continuous elimination of low density lipoproteins (LDL) by heparin precipitation: first clinical application. Trans. Am. Soc. Artif. Intern. Organs. 32:1986;104-107
46. Park J.W., Merz M., Braun P. Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. Atherosclerosis. 139:1998;401-409
47. Richter W.O., Donner M.G., Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther. Apher. 3:1999;203-208
48. Schaumann D., Welch-Wichary M., Voss A., Schmidt H., Olbricht C.J. Prospective cross-over comparison of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia. Eur. J. Clin. Invest. 26:1996;1033-1038
49. Schulzeck P., Olbricht C.J., Koch K.M. Long-term experience with extracorporeal low-density lipoprotein cholesterol removal by dextran sulfate cellulose adsorption. Clin. Investig. 70:1992;99-104